Pharming Group (OTCMKTS:PHGUF) Stock Crosses Below 50 Day Moving Average of $1.44

Pharming Group (OTCMKTS:PHGUF) shares passed below its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $1.44 and traded as low as $1.36. Pharming Group shares last traded at $1.40, with a volume of 98,906 shares changing hands.

PHGUF has been the topic of several recent analyst reports. ValuEngine lowered Pharming Group from a “hold” rating to a “sell” rating in a research note on Tuesday, March 31st. Zacks Investment Research downgraded Pharming Group from a “buy” rating to a “hold” rating in a report on Thursday, May 28th.

The company has a fifty day moving average of $1.44 and a two-hundred day moving average of $1.42.

Pharming Group (OTCMKTS:PHGUF) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.01 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.02 by ($0.01). The company had revenue of $54.47 million during the quarter, compared to the consensus estimate of $52.52 million. On average, equities research analysts anticipate that Pharming Group will post 0.09 earnings per share for the current year.

About Pharming Group (OTCMKTS:PHGUF)

Pharming Group N.V., a specialty pharmaceutical company, develops and produces human therapeutic proteins for the treatment of rare diseases and unmet medical needs. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of angioedema attacks in patients with acute hereditary angioedema (HAE) in Europe, the United States, Israel, European Union countries, Norway, Iceland, and Liechtenstein.

Featured Story: Calculating net profit and net profit margin ratio

Receive News & Ratings for Pharming Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharming Group and related companies with's FREE daily email newsletter.